Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

Catherina X Pan; Mofei Liu; Charles B Lau; William C Lau; Daniel Y Kim; Shahin A Saberi; Rachael Rowley; Ruhi Kanwar; Anita Giobbie-Hurder; Nicole R LeBoeuf; Vinod E Nambudiri

doi:10.1016/j.jaad.2023.11.037

Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

J Am Acad Dermatol. 2024 Apr;90(4):826-829. doi: 10.1016/j.jaad.2023.11.037. Epub 2023 Nov 30.

Authors

Affiliations

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Boston University, Boston, Massachusetts.
⁴ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Boston University School of Medicine, Boston, Massachusetts.
⁵ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
⁶ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cutaneous Oncology, Boston, Massachusetts.
⁷ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cutaneous Oncology, Boston, Massachusetts. Electronic address: [email protected].

PMID: 38040339
DOI: 10.1016/j.jaad.2023.11.037

No abstract available

Keywords: BRAF; NRAS; histopathology; immune checkpoint inhibitor; immune-related adverse events; immunotherapy; irAEs; lymphovascular invasion; melanoma; mitotic rate; regression; toxicity; tumor infiltrating lymphocytes; tumor mutation.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Immune Checkpoint Inhibitors / adverse effects
Immunotherapy
Melanoma* / pathology
Skin Neoplasms* / chemically induced
Skin Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antibodies, Monoclonal